Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research.
Joseph Junior DambaKatie BodensteinPaola LavinJessica DruryHarmehr SekhonChristel RenouxEmilie TrinhSoham RejKyle T GreenwayPublished in: CNS drugs (2022)
Despite the heterogeneity of findings, owing to varying methodologies and research challenges, recent studies strongly suggest that lithium is associated with an increased risk of chronic kidney disease and nephrogenic diabetes insipidus, especially in older adults and long-term lithium users. Clinicians should balance the harms of lithium against its established benefits, and ensure adequate monitoring and management of comorbidities in all patients. Weaker evidence suggests that antiepileptics such as valproate and antipsychotics result in comparatively less harm to the kidney than lithium, but warrant monitoring because of multiple direct and indirect mechanisms for potential kidney adverse events. Antidepressants do not have clear kidney adverse effects and appear safe (though potentially less effective) in the setting of kidney disease. Other classes of psychotropic drugs have received little research interest. Further research is warranted, particularly into specific antiepileptics and antipsychotics, and careful attention should be paid to mitigating important sources of bias such as confounding by indication.
Keyphrases
- end stage renal disease
- chronic kidney disease
- solid state
- peritoneal dialysis
- type diabetes
- ejection fraction
- newly diagnosed
- cardiovascular disease
- physical activity
- working memory
- prognostic factors
- major depressive disorder
- metabolic syndrome
- single cell
- drinking water
- emergency department
- climate change
- drug induced
- glycemic control
- skeletal muscle
- insulin resistance
- case control
- adverse drug